Research programme: drug discovery - Advinus Therapeutics/Takeda
Latest Information Update: 09 Nov 2014
At a glance
- Originator Advinus Therapeutics; Takeda
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders; Inflammation; Metabolic disorders
Most Recent Events
- 09 Nov 2014 Development is ongoing in Japan and India
- 03 Oct 2012 Early research in Metabolic disorders in India (unspecified route)
- 03 Oct 2012 Early research in Inflammation in India (unspecified route)